Effects of psilocybin therapy on personnality structure ERRITZOE D., ROSEMAN L., NOUR M.M., MacLEAN K., KAELEN M., NUTT D.J., CARHART-HARRIS R.L. Acta Psychiatrica Scandinavica, 2018, 1-11. DOI : 10.1111/acps.12904 . Objective : To explore whether psilocybin with psychological support modulates personality parameters in patients suffering from treatment-resistant depression (TRD). Method : Twenty patients with moderate or severe, unipolar, TRD received oral psilocybin (10 and 25 mg, one week apart) in a supportive setting. Personality was assessed at baseline and at 3-month follow-up using the Revised NEO Personality Inventory (NEO-PI-R), the subjective psilocybin experience with Altered State of Consciousness (ASC) scale, and depressive symptoms with QIDS-SR16. Results : [...]
Lire la suiteQuality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression Leor Roseman, David J. Nutt, Robin L. Carhart-Harris Psychedelic Research Group, Department of Medicine, Imperial College London, London, United Kingdom Frontiers in Pharmacology, 2018, 8, article 974. Doi : 10.3389/fphar.2017.00974 . Introduction : It is a basic principle of the “psychedelic” treatment model that the quality of the acute experience mediates long-term improvements in mental health. In the present paper we sought to test this using data from a clinical trial assessing psilocybin for treatment-resistant depression (TRD). In line with previous reports, we hypothesized that the occurrence and magnitude of Oceanic Boundlessness (OBN) [...]
Lire la suiteIndividual Experiences in Four Cancer Patients Following Psilocybin-Assisted Psychotherapy Tara C. Malone, Sarah E. Mennenga, Jeffrey Guss, Samantha K. Podrebarac, Lindsey T. Owens, Anthony P. Bossis, Alexander B. Belser, Gabrielle Agin-Liebes, Michael P. Bogenschutz and Stephen Ross Frontiers in Pharmacology, 2018, 9, 256 doi: 10.3389/fphar.2018.00256 Abstract : A growing body of evidence shows that existential and spiritual well-being in cancer patients is associated with better medical outcomes, improved quality of life, and serves as a buffer against depression, hopelessness, and desire for hastened death. Historical and recent research suggests a role for psilocybin-assisted psychotherapy in treating cancer-related anxiety and depression. A double-blind controlled trial was performed, where 29 [...]
Lire la suiteClinical Interpretations of Patients Experience in a Trial of Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder BOGENSCHUTZ M.P., PODREBARAC S.K., DUANE J.H., AMEGADZIE S.S., MALONE T.C., ROSS L.T., MENNENGA S.E. Frontiers in Pharmacology, 2018, 9, article 100. Doi : 10.3389/fphar.2018.00100 Abstract : After a hiatus of some 40 years, clinical research has resumed on the use of classic hallucinogens to treat addiction. Following completion of a small open-label feasibility study, we are currently conducting a double-blind placebo-controlled clinical trial of psilocybin-assisted treatment of alcohol use disorder. Although treatment effects cannot be analyzed until the study is complete, descriptive case studies provide a useful window into the therapeutic process [...]
Lire la suitePsilocybin with psychological support for treatment resistant depression : six-month follow-up R. L. Carhart-Harris, M. Bolstridge, C. M. J. Day, J. Rucker, R. Watts, D. E. Erritzoe, M. Kaelen, B. Giribaldi, M. Bloomfield, S. Pilling, J. A. Rickard, B. Forbes, A. Feilding, D. Taylor, H. V. Curran, D. J. Nutt Psychopharmacology, 2017 https://doi.org/10.1007/s00213-017-4771-x Abstract : Rationale : Recent clinical trials are reporting marked improvements in mental health outcomes with psychedelic drug-assisted psychotherapy. Objectives : Here, we report on safety and efficacy outcomes for up to 6 months in an open-label trial of psilocybin for treatment-resistant depression. Methods : Twenty patients (six females) with (mostly) severe, unipolar, treatment-resistant [...]
Lire la suitePsychedelics and hypnosis : Commonalities and therapeutic implications Clément E. Lemercier, Devin B. Terhune Journal of Psychopharmacology, 2018, 32, 7, 732-740. DOI : 10.1177/0269881118780714 Abstract Background : Recent research on psychedelics and hypnosis demonstrates the value of both methods in the treatment of a range of psychopathologies with overlapping applications and neurophenomenological features. The potential of harnessing the power of suggestion to influence the phenomenological response to psychedelics toward more therapeutic action has remained unexplored in recent research and thereby warrants empirical attention. Aims : Here we aim to elucidate the phenomenological and neurophysiological similarities and dissimilarities between psychedelic states and hypnosis in order to revisit [...]
Lire la suiteEffective connectivity changes in LSD-induced altered states of consciousness in humans Katrin H. Preller, Adeel Razib, Peter Zeidman, Philipp Stämpflif, Karl J. Friston, and Franz X. Vollenweider Proceedings of the National Academy of Sciences ,· January 2019 DOI: 10.1073/pnas.1815129116 Abstract : Psychedelics exert unique effects on human consciousness. The thalamic filter model suggests that core effects of psychedelics may result from gating deficits, based on a disintegration of information processing within cortico–striato–thalamo-cortical (CSTC) feedback loops. To test this hypothesis, we characterized changes in directed (effective) connectivity between selected CTSC regions after acute administration of lysergic acid diethylamide (LSD), and after pretreatment with Ketanserin (a selective serotonin [...]
Lire la suiteClassic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population Peter S Hendricks, Christopher B Thorne, C Brendan Clark, David W Coombs, and Matthew W Johnson Journal of Psychopharmacology · January 2015 DOI: 10.1177/0269881114565653 · Abstract : Mental health problems are endemic across the globe, and suicide, a strong corollary of poor mental health, is a leading cause of death. Classic psychedelic use may occasion lasting improvements in mental health, but the effects of classic psychedelic use on suicidality are unknown. We evaluated the relationships of classic psychedelic use with psychological distress and suicidality among over 190,000 USA [...]
Lire la suiteReducing the risks of drug use: The case for set and setting PHIL DALGARNO & DAVID SHEWAN Addiction Research and Theory, 2005, 13, 3, 259–265 Abstract : The central proposition of this article is that if people are thoughtful, well-prepared and aware of the means and best environments for using a particular drug, then the risks associated with the use of a particular drug – any drug – can be minimal. The types of drugs discussed in this context focus on those assumed to be the most ‘addictive’ – heroin and cocaine – to those less well-known but potentially more hazardous to use without [...]
Lire la suiteCeremonial ‘Plant Medicine’ use and its relationship to recreational drug use : an exploratory study Caroline Dorsen, Joseph Palamar and Michele G. Shedlin Addiction Research & Theory, 2018 https://doi.org/10.1080/16066359.2018.1455187 ABSTRACT Background : The ceremonial use of psychoactive/hallucinogenic plant based drugs, such as ayahuasca, psilocybin and others, is a growing trend in the United States (US) and globally. To date, there has been little research documenting how many people are using psychoactive substances in this context, who the users are, what benefits/risks exist in the use of these drugs and the relationship between ceremonial drug use and recreational drug use. In this paper we describe a [...]
Lire la suite